

Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.
Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

CIN No. L52520TG1989PLC009679

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2015

PART - I

(Amt in lakhs)

S. No	Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2015	30.06.2015	30.09.2014	30.09.2015	30.09.2014	31.03.2015
		Un-audited			Un- Audited		Audited
1	Income from Operations						
	(a) Net Sales/Income from	31.66	57.49	45.29	89.15	90.46	173.04
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations	31.66	57.49	45.29	89.15	90.46	173.04
2	Expenses				0.00		
	a. Consumption of raw materials	5.06	5.10	1.55	10.16	4.46	0.00
	b. Purchases of stock-in-trade	21.18	21.61	25.14	42.79	46.39	104.19
	c. Increase/decrease in stock in trade and WIP	(4.91)	5.57	3.03	0.66	0.94	(0.50)
	d. Power & Fuel	0.00	0.00	0.00	0.00	0.00	0.00
	e. Sales Tax and other Taxes	0.00	0.00	0.00	0.00	0.00	0.00
	f. Employees Cost	6.07	5.18	4.87	11.25	9.31	18.20
	g. Depreciation	2.52	2.42	1.68	4.94	3.36	13.71
	h. Other expenditure	11.57	12.43	11.65	24.00	34.47	60.31
	Total	41.49	52.31	47.92	93.80	98.93	195.91
	(Any item exceeding 10% of the	0.00	0.00	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations	(9.83)	5.18	(2.63)	(4.65)	(8.47)	(22.87)
4	Other Income	4.50	0.00	4.95	4.50	12.53	12.42
5	Profit / (Loss) from Ordinary	(5.33)	5.18	2.32	(0.15)	4.06	(10.45)
6	Finance Cost	0.81	0.03	0.00	0.84	0.00	0.15
7	Profit / (Loss) from Ordinary	(6.14)	5.15	2.32	(0.99)	4.06	(10.60)
8	Exceptional Items - Expenditure /	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary	(6.14)	5.15	2.32	(0.99)	4.06	(10.60)
10	Tax expense						
	a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00	0.00
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00	0.00	4.05
	c) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+) / Loss (-) from	(6.14)	5.15	2.32	(0.99)	4.06	(6.55)
12	Extraordinary items (net of tax	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit (+) / Loss (-) for the	(6.14)	5.15	2.32	(0.99)	4.06	(6.55)
14	Paid-up equity share capital (Face value of the Share is Rs 10/-	336.31	336.31	336.31	336.31	336.31	336.31
15	Reserves excluding Revaluation	9.94	9.94	9.94	9.94	9.94	9.94
16	Earnings Per Share (before						
	a) Basic	(0.18)	0.15	0.07	(0.03)	0.12	(0.19)
	b) Diluted	(0.18)	0.15	0.07	(0.03)	0.12	(0.19)
17	Earnings Per Share (after extra-						
	a) Basic	(0.18)	0.15	0.07	-0.03	0.12	(0.19)
	b) Diluted	(0.18)	0.15	0.07	-0.03	0.12	(0.19)
PART - II							
A. Particulars of Shareholding							
1	Public shareholding						
	- Number of shares	3,183,906	3,155,397	3,174,393	3,183,906	3,166,405	3,166,405
	- Percentage of shareholding	93.49%	92.66%	93.21%	93.49%	92.98%	92.98%
2	Promoters and Promoter Group						
	Shareholding						
	a Pledged/Encumbered - No. of Shares	Nil	Nil	NIL	Nil	Nil	Nil
	percentage of shares	Nil	Nil	NIL	Nil	Nil	Nil

Chandra
Pharmaids Pharmaceuticals Limited
4-4-211/212/11-12, Inderbagh
Sultan Bazar
Hyd-95

		(as a % of the total shareholding of promoter and promoter group)						
		percentage of shares	Nil	Nil	NIL	Nil	Nil	Nil
		(as a % of the total share capital of the Company)						
	b	Non - encumbered						
		Number of shares	221,594	250,103	231,107	221,594	239,095	239,095
		percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
		percentage of shares (as a % of the total sharecapital of the company)	6.51%	7.34%	6.79%	6.51%	7.02%	7.02%
B.	Particulars		6 months ended 30/09/2015					
	INVESTOR COMPLAINTS							
	Pending at the beginning of the quarter		Nil					
	Received during the quarter		Nil					
	Disposed of during the quarter		Nil					
	Remaining unresolved at the end of the quarter		Nil					
Notes:								
1) The above unaudited results of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th Nov, 2015.								
2) Figures for the previous Year/Quarter have been rearranged/regrouped wherever necessary.								
3) The Company's exclusive business is manufacturing and selling of Drugs Formulation and as such this is the only reportable segment as per Accounting Standard-17 on segment reporting issued by the ICAI								
4) Provisions for Income Tax and Deferred Tax will be made at the end of the Financial Year								
PLACE : HYDERABAD			For PHARMAIDS PHARMACEUTICALS LIMITED					
DATE : 14.11.2015			Chairman & Managing Director					

Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad - 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 30.09.2015

(Rs. In lakhs)

Particulars		As on 30.09.2015	As on 31.03.2015
		Audited	Audited
A	EQUITY AND LIABILITY		
1	SHARE HOLDERS' FUNDS:		
	(a) Share Capital	336.31	336.31
	(b) Reserves and Surplus	-165.73	-164.74
	Sub Total - Shareholders Fund	170.58	171.57
2	Share application money pending allotment	0.00	0.00
3	Minority Interest	0.00	0.00
4	Non-Current Liabilities		
	(a) Long term Borrowings	34.79	20.66
	(b) Deferred Tax (Net)	6.17	6.17
	(c) Other Long term Liabilities	0.00	0.00
	(d) Long Term Provisions	0.00	0.00
	Sub-Total - Non Current Liabilities	40.96	26.83
5	Current Liabilities		
	(a) Short Term Borrowings	7.30	9.02
	(b) Trade Payables	53.50	40.95
	(c) Other Current Liabilities	5.34	3.90
	(d) Short Term Provisions	0.00	0.00
	Sub-Total - Current Liabilities	66.14	53.87
	TOTAL EQUITY AND LIABILITY	277.68	252.27
B	ASSETS		
1	Non-Current Assets		
	(A) Fixed Asset	46.34	46.30
	(b) Non Current Investment	0.00	0.00
	(c) Deferred Yax Asset (Net)	0.00	0.00
	(d) Long term Loans and Advances	43.17	46.87
	(e) Other Non-Current Assets		
	Sub-Total Non-Current Assets	89.51	93.17
2	Current Assets		
	(a) Current Investments	0.00	0.00
	(b) Inventories	26.24	28.98
	(c) Trade Receivables	124.75	111.02
	(d) Cash and Cash equivalents	37.18	19.10
	(e) Short Term Loans and Advances	0.00	0.00
	(f) Other Current Assets	0.00	0.00
	Sub-Total Current Assets	188.17	159.10
	TOTAL	277.68	252.27

For PHARMAIDS PHARMACEUTICALS LIMITED



Dr. Ghisulal Jain
 Chairman & Managing Director

PLACE : HYDERABAD

DATE :14.11.2015

Date :

LIMITED REVIEW REPORT


We have reviewed the accompanying statement of un-audited financial results of **M/S. PHARMAIDS PHARMACEUTICALS LIMITED, HYDERABAD** for the quarter ended 30th September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter Group Shareholding' which has been traced from disclosures made by the management and has not been audited by us. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an opinion. We have not performed an audit and accordingly we do not express such an opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.

Based on our review conducted as above, and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognized policies and practices generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchange including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rakesh S Jain & Associates
Chartered Accountants
Firm Registration No. 010129S



B. Ramesh Kumar
(B. Ramesh Kumar)
Partner
M. No. 200304

Date: 14.11.2015
Place: Hyderabad.